Nanologica Announces Nomination Committee for the Annual General Meeting 2023

In accordance with the resolution at the Annual General Meeting (“AGM”) on June 2, 2022, the chairman of the board has contacted the company’s three largest owners or ownership groups in terms of votes as of September 30, 2022, each of whom has appointed a representative to constitute the nomination committee of Nanologica AB for the 2023 AGM.

The nomination committee for Nanologica AB’s 2023 AGM thus consists of the following three members:

  • Carl-Johan Spak (Flerie Invest AB)
  • Lennart Francke (Swedbank Robur Microcap)
  • Joakim Persson (Vega Bianca AB)

The nomination committee together represents 47.9 percent of the shares and the votes in Nanologica AB as of September 30, 2022.

The task of the nomination committee is to present proposals to the 2023 AGM for the election of the chairman of the meeting, the number of board members to be elected by the meeting, the election of the chairman of the board and other members of the board of directors, fees and any remuneration for committee work, the election of auditors (if applicable) and auditor’s fees, as well as proposals for the principles that shall apply to the composition and work of the nomination committee for the next AGM.

The 2023 AGM will take place in Stockholm on the 4th of May 2023. Shareholders who wish to submit proposals to the nomination committee may do so by e-mail to no later than January 31, 2023. The nomination committee’s proposal will be presented in the notice convening the AGM and on the company’s website.


 For further information, please contact:
Gisela Sitbon, chairman of the board
Ph: +46 70 282 55 58 or e-mail:


About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market since 29 mars, 2022. For further information, please visit


2022-10-20 Nanologica Announces Nomination Committee for the Annual General Meeting 2023

Share this: